A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD)
Latest Information Update: 16 Jan 2024
At a glance
- Drugs LX-102-C01 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Innostellar Biotherapeutics
Most Recent Events
- 16 Jan 2024 New trial record